On this page:OverviewPublicationsResearchersKey papersJournalsOpen accessInstitutions
ScholarIQanswers from OpenAlex

Peroxisome Proliferator-Activated Receptors

TopicLeading institutions, researchers & key papers

Peroxisome Proliferator-Activated Receptors is a topic indexed in ScholarIQ from OpenAlex.

What is known about Peroxisome Proliferator-Activated Receptors?

ScholarIQrecord summary

This cluster of papers focuses on the Peroxisome Proliferator-Activated Receptors (PPARs), a group of nuclear receptors that play a crucial role in regulating metabolism, inflammation, lipid physiology, and various metabolic diseases such as obesity and diabetes. The cluster explores the diverse biology, mechanisms of action, and therapeutic implications of PPARs, including their involvement in transcriptional regulation and the role of fatty acid-binding proteins.

How many works does Peroxisome Proliferator-Activated Receptors have?

ScholarIQindexed works

Peroxisome Proliferator-Activated Receptors has 233 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

What is the OpenAlex record for Peroxisome Proliferator-Activated Receptors?

ScholarIQopenalex

The OpenAlex for Peroxisome Proliferator-Activated Receptors is on the source record.

What are the most-cited papers on Peroxisome Proliferator-Activated Receptors?

ScholarIQmost cited works
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
John Dormandy, B Charbonnel, D.J.A. Eckland, Erland Erdmann, Massimo Massi‐Benedetti, Ian K. Moules, Allan M. Skene, Meng H. Tan, Pierre J. Lefèbvre, Gordon Murray, Eberhard Standl, Robert G. Wilcox, Lars Wilhelmsen, John Betteridge, Kåre I. Birkeland, Alain Golay, Robert J. Heine, László Korányi, Markku Laakso, Marian Mokáň, Antanas Norkus, Valdis Pīrāgs, Toomas Podar, André Scheen, Werner A. Scherbaum, Guntram Schernthaner, Ole Schmitz, J Skrha, Ulf Smith, J Tatoń
The Lancet. 20054,139 CitationsOPEN ACCESS
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
Steven E. Kahn, Steven M. Haffner, Mark Heise, William H. Herman, Rury R. Holman, Nigel C. Jones, Barbara G. Kravitz, John M. Lachin, Mark O’Neill, Bernard Zinman, Giancarlo Viberti
New England Journal of Medicine. 20062,958 Citations
Short-Chain Fatty Acids Protect Against High-Fat Diet–Induced Obesity via a PPARγ-Dependent Switch From Lipogenesis to Fat Oxidation
Gijs den Besten, Aycha Bleeker, Albert Gerding, Karen van Eunen, Rick Havinga, Theo H. van Dijk, Maaike H. Oosterveer, Johan W. Jonker, Albert K. Groen, Dirk‐Jan Reijngoud, Barbara M. Bakker
Diabetes. 20151,114 Citations
Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
Akira Okuno, Hiroyuki Tamemoto, Kazuuki TOBE, Kohjiro Ueki, Yusaku Mori, K Iwamoto, Kazuhiko Umesono, Y. Akanuma, Takuya Fujiwara, Hiroyoshi Horikoshi, Y Yazaki, Takashi Kadowaki
Journal of Clinical Investigation. 1998999 CitationsOPEN ACCESS
Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy
Florian Eichler, Christine Duncan, Patricia L. Musolino, Paul J. Orchard, Satiro De Oliveira, Adrian J. Thrasher, Myriam Armant, Colleen Dansereau, Troy C. Lund, Weston P. Miller, Gerald V. Raymond, Raman Sankar, Ami J. Shah, Caroline Sevin, H. Bobby Gaspar, Paul Gissen, Hernán Amartino, Drago Bratkovic, Nicholas Smith, Asif Paker, Esther Shamir, Tara O’Meara, David Davidson, Patrick Aubourg, David A. Williams
New England Journal of Medicine. 2017599 Citations

Where is Peroxisome Proliferator-Activated Receptors research published, and who funds it?

ScholarIQvenues & funding sources

TOP FUNDERS

National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock

How much of the research on Peroxisome Proliferator-Activated Receptors is open access?

ScholarIQopen access share
47%OPEN ACCESS
Gold
0%
Green
20%
Hybrid
7%
Bronze
20%
Closed
53%

Related on ScholarIQ

470M+ articles · 14-day free trial